The European challenges of funding orphan medicinal products.

ABSTRACT:

Background

Funding of orphan medicinal products (OMPs) is an increasing challenge in the European Union (EU).

Objectives

To identify the different methods for public funding of OMPs in order to map the availability for rare disease patients, as well as to compare the public expenditures on OMPs in 8 EU member states.

Methods

Information on the reimbursement status of 83 OMPs was collected in 8 countries by distinguishing standard and special reimbursements. In two consecutive years, the total public expenditures on OMPs were calculated by using annual EUR exchange rates. Annual total public expenditures were calculated per capita, and as a proportion of GDP, total public pharmaceutical and healthcare budgets. Differences between countries were compared by calculating

SUBMITTER: Szegedi M 

PROVIDER: S-EPMC6219168 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature